Analysis Group Announces Two Senior-Level Promotions and Welcomes New Vice President
Analysis Group is pleased to announce the promotion of Marianne Cunnington and Yan Song to managing principal and to welcome vice president Enno Eilts to the firm.
“These promotions recognize the accomplishments of Marianne and Yan, whose expertise in epidemiology, real-world evidence (RWE), and economic modeling helps our clients generate and interpret evidence to support regulatory, payer, and strategic decisions across the life cycle of pharmaceuticals. Within the firm, they have also helped build our health care teams in London and Boston and mentored colleagues at all levels. We are delighted to welcome Enno, who brings more than 20 years of experience in competition economics, particularly in follow-on competition litigation and damages quantification across Europe,” said Pierre Cremieux, CEO of Analysis Group.
New Managing Principals
Marianne Cunnington specializes in regulatory epidemiology, including the design and execution of real-world post-marketing safety and effectiveness studies, as well as real-world studies to support the approval of new products through innovative regulatory pathways. With more than 20 years of experience, she has research expertise in the design, negotiation, and execution of real-world components of risk management plans for multiple new product submissions with regulators in the US, UK, Europe, Japan, and South Korea; post-approval safety studies in the EU; post-marketing requirement and commitment studies in the US; and pregnancy registries. Before joining Analysis Group, Dr. Cunnington held senior epidemiology positions at Novartis Vaccines and GlaxoSmithKline (GSK), where she focused on the generation of real-world evidence to support the development and life cycle management of vaccines and pharmacological therapies. At GSK, she chaired the peer review forum for all pharmaceutical RWE projects. She serves on the board of the International Society for Pharmacoepidemiology as an elected representative of European industry and service providers.
Yan Song is an epidemiologist with training in medicine and biostatistics and extensive experience applying health economics and outcomes research (HEOR) to complex health care decisions. He advises pharmaceutical and biotech clients, as well as health technology organizations, on evidence generation strategies and leads the design and implementation of advanced RWE studies and pharmacoeconomic modeling solutions. Dr. Song has consulted across indications on multiple pharmaceutical products as well as novel pipeline therapies. Beyond generating evidence, he helps clients critically interpret research findings, assess the strengths and limitations of available evidence, and translate results into actionable insights to support clinical, regulatory, payer, and strategic decision making. He conducts research to evaluate and compare the clinical, economic, and humanistic impacts of diseases and treatments across therapeutic areas such as oncology, hematology, cardiology, and infectious diseases. His work spans disease epidemiology and causal inference, burden of illness, treatment and management patterns, comparative effectiveness research, and individualized medicine. Dr. Song has published more than 100 peer-reviewed journal articles and given more than 140 presentations at international conferences on medical and health care research.
New Vice President
Enno Eilts is a specialist in competition economics with more than 20 years of experience and a focus on follow-on competition litigation and damages quantification. In this context, he advises claimants and defendants in Germany, the UK, the Netherlands, and elsewhere in Europe. His case work includes matters involving e-commerce, trucks, rail tracks, sugar, vehicle shipping, high-voltage cables, automobile parts, and air cargo, and his broader competition work includes merger analysis, market and cartel investigations, abuse of dominance, and state aid. Mr. Eilts has advised parties before courts and competition authorities, including the European Commission, the UK Competition and Markets Authority, and the New Zealand Commerce Commission, and has consulted to public bodies such as the Organisation for Economic Co-operation and Development (OECD). He has published in the Competition Law Journal and has taught competition economics at the Toulouse School of Economics and the University of Johannesburg. Mr. Eilts is listed in Global Competition Review’s Lexology Index: Consulting Experts – Competition Economists. Before joining Analysis Group, he was a partner at Oxera.
Associated People
Marianne Cunnington
Managing PrincipalDr. Cunnington specializes in regulatory epidemiology, including the design and execution of real-world post-marketing safety and effectiveness studies, as well as real-world studies to support the approval of new products through innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for new product submissions with regulators across multiple geographies (US, UK, Europe, Japan, South Korea); post-approval safety studies in the EU; post-marketing requirement and commitment studies in the US; and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington spent more than 20 years as a pharmaceutical industry epidemiologist focusing on the generation of real-world evidence (RWE) to support the development and life cycle management of vaccines and pharmacological therapies. Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical RWE projects, provided epidemiological expertise for the company’s Global Safety Board, and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington serves on the board of the International Society for Pharmacoepidemiology as an elected representative of European industry and service providers.
Enno Eilts
Vice PresidentMr. Eilts is a specialist in competition economics with more than 20 years of experience and a focus on follow-on competition litigation and damages quantification. In this context, he advises claimants and defendants in Germany, the UK, the Netherlands, and elsewhere in Europe. Mr. Eilts’s case work includes matters involving e-commerce, trucks, rail tracks, sugar, vehicle shipping, high-voltage cables, automobile parts, and air cargo.
His broader competition work includes merger analysis, market and cartel investigations, abuse of dominance, and state aid. He has advised parties before courts and competition authorities, including the European Commission, the UK Competition and Markets Authority, and the New Zealand Commerce Commission, and has consulted to public bodies such as the Organisation for Economic Co-operation and Development (OECD).
Mr. Eilts has published on competition issues, including in the Competition Law Journal, and coauthored an OECD Round Table paper on ports and port services. He has taught competition economics and utility regulation, including Quantifying Damages at the Toulouse School of Economics, Advanced Competition Economics at the University of Johannesburg, judicial training on quantifying antitrust damages for the European Commission and the OECD, and state aid modules at the Academy of European Law and the European Institute of Public Administration.
Mr. Eilts is listed in Global Competition Review’s Lexology Index: Consulting Experts – Competition Economists. Before joining Analysis Group, he was a partner at Oxera. Earlier, he worked at the UK Competition Commission and the New Zealand Commerce Commission.